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Surrlmary 
We have generated for the first time monoclonal antibodies (mAbs) specific for topoisomerase 
I (topo I) from scleroderma patients, and tight skin mice which develop a sderoderma-like syndrome. 
The epitope specificity of these antibodies has been determined using a series of fusion proteins 
containing contiguous portions of topo I polypeptide. Western blot analysis demonstrated that 
both human and mouse mAbs bound strongly to fusion protein C  encompassing the NH2- 
terminal portion of the enzyme, and weakly to fusion proteins F and G containing regions close 
to the COOH-terminal end of the molecule. This crossreactivity is related to a tripeptide sequence 
homology in F, G, and C fusion proteins. It is interesting that a pentapeptide sequence homologous 
to that in fusion protein C was identified in the UL70 protein of cytomegalovirus, suggesting 
that activation of autoreactive  B cell clones by molecular mimicry is possible. Both human and 
mouse mAbs exhibiting the same antigen specificity,  also share an interspecies cross-reactive idiotope. 
These data suggest that B cell clones producing antitopo autoantibodies present in human and 
mouse repertoire are conserved during phylogeny, and are activated during the development of 
scleroderma disease. 
p lrogressive systemic sclerosis (PSS)  1 is a connective tissue 
disease affecting skin (scleroderma)  and internal organs 
such as lungs, heart, kidneys, and gastrointestinal tract. Au- 
toantibodies to various nuclear proteins (1-4)  and collagens 
(5) are found in 40-95% of patients with scleroderma.  The 
major antinuclear antibodies found in patients with PSS are 
anti-Sd70 autoantibodies. Sc170 antigen represents a crude 
nuclear extract from thymus that is used for clinical diag- 
nosis of scleroderma.  Later studies show that topoisomerase 
I (topo I) is the major target autoantigen present in Sc170 
preparation (2). These autoantibodies are not present in pa- 
tients with other systemic autoimmune diseases such as sys- 
temic lupus erythematosus (SLE), Sjogren's syndrome, or rheu- 
I Abbreviations  used in this paper:. CMV, cytomegalovirus; GST, glutathione- 
S-transferase; PSS, progressive  systemic sclerosis; SLE, systemic lupus 
erythematosus;  Sm, Smith antigen;  topo I, topoisomerase I; TSK, tight 
skin mouse; VH, variable region of heavy chain. 
matoid arthritis. Recently, we have demonstrated the presence 
of anti-topo I antibodies in tight skin mice (TSK) (6). This 
mutant strain develops cutaneous hyperplasia with histopatho- 
logical characteristics similar to those of human scleroderma 
(7), subsequent to hyperproduction of collagen. Furthermore, 
we have shown that the IgG fraction of scleroderma patients' 
sera with antitopo I antibodies, inhibited the binding of TSK 
mAbs to topo I (6). These results  strongly suggested that 
antitopo I autoantibodies present in the sera of scleroderma 
patients and TSK mice recognize similar or very dosely related 
epitopes. 
To define these epitopes,  we have used antitopo I mono- 
clonal autoantibodies obtained from scleroderma patients and 
TSK mice in competitive inhibition assays and Western blot- 
ting analysis using recombinant topo I fusion proteins con- 
taining defined portions of topo I. The results presented in 
this study demonstrate that human mAbs inhibit the binding 
of TSK mAbs to topo I, and that both human and mouse 
mAbs bind to the same peptide fragments of the enzyme ex- 
pressed as fusion protein. 
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mAbs.  The  preparation  and  determination  of the  binding 
specificity of anti-tope I mAbs derived froal TSK mice have been 
previously described  (6). EBV-transformed  B cell lines were pre- 
pared according to the method described  by Davidson et al. (8). 
The cell lines producing antitopo I antibodies were subcloned by 
diluting one or three cells/well  in RPMI medium supplemented 
with 10% FCS, and 20% of supernatant from murine macrophage 
cell line J774. The supernatants  from the subclones were rescreened 
by RIA. GM17-1, L350-7, and GM3-16 are TSK antitopo I mAbs 
previously described (6). G17-13, a TSK mAb recognizing a cross- 
reactive Id on antitopo I antibodies was previously described (6). 
Antigens.  Highly purified calf thymus topoisomerase I of 70 
kD used in this study was obtained from Bethesda Research Labora- 
tories (Bethesda,  MD).  Sc170 Ag was obtained from Alpha An- 
tigens,  Inc. (Columbia, Me). Rat type I collagen was a kind gift 
from Dr. R. Holmdahl (Uppsala University, Uppsala, Sweden) and 
X phage DNA was prepared in our laboratory and used as dsDNA. 
RNA polymerase was purchased from Pharmacia Fine Chemicals 
(Piscataway, NJ). Recombinant proteins consisting of various por- 
tions of tope I fused to glutathione-S-transferase (GST) have been 
described (Cram, D. S., N. Fisicaro, J. McVeilage, R. L. Coppel, 
and L. C. Harrison, manuscript submitted for publication). The 
peptide fragments of tope I, with corresponding amino acid residues 
contained in each fusion protein, are shown in Fig.  1. 
Antigen-binding Studies.  (a)  Direct binding  assay. Microtiter 
plates were coated with tope I (3/~g/ml) in carbonate buffer pH 
9.6  at  4~  overnight.  After washing,  the plates  were blocked 
with 1% BSA in PBS for 1 h, washed three times,  and incubated 
with chromatographically  purified TSK or human antibodies. After 
extensive  washing,  50,000  cpm  of 12SI-labeled rat  monoclonal 
anti-mouse K antibody or rabbit F(ab')2 anti-human 3, antibody 
was  added and incubated for another 2  h.  After washing,  the 
bound radioactivity was measured in a 3' spectrometer. The puri- 
fication of mAbs from the culture medium was  carried out on 
Sepharose  4B, (Pharmacia  Fine Chemicals,  Piscataway, NJ) cou- 
pled with monoclonal rat anti-mouse ic antibody or rabbit F(ab')~ 
anti-human '7 antibody columns, as previously described (6). 
Competitive Inhibition Assay.  Pilot experiments were carried out 
to determine the concentration of mAbs giving 50% of maximal 
binding to tope I-coated plates. Antibodies at the concentrations 
corresponding to 50% binding were incubated for 30 rain at room 
temperature with various amounts of tope I, type I collagen, RNA 
polymerase, or dsDNA, and then transferred to tope I-coated plates. 
The binding of antitopo I antibodies was measured as described 
above. Assay of inhibition of the binding of TSK mAb by human 
mAb was carried out by addition of various  amounts of human 
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Figure 2.  Dose-effect inhibition of binding of human mAb N188 to 
topo I by topo I, collagen I, dsDNA, and RNA polymerase. 
mAbs  and  50,000 cpm  of 12SI-labeled TSK mAb  to  microtiter 
plates  coated with tope I. 
Western Blotting.  Purified tope I fusion proteins were run on 
7.5 % polyacrylamide gels in the presence of SDS-PAGE. Separated 
proteins were electrophoretically transferred to nitrocellulose filters 
(Schleicher & Schuell, Inc., Keene, NH) at 100 V for 5 h at 4~ 
The filters were blocked with 5% BSA and then incubated with 
TSK mouse or human mAbs (2/~g/ml) or 1:800 dilution of an- 
titopo I positive serum from a scleroderma patient, in PBS con- 
taining 5% BSA and 0.1% Tween 20. After extensive washing with 
PBS containing 0.1% Tween 20, filters were incubated for 90 min 
at room temperature with lZSI-rat anti-mouse K mAb in the case 
of filters incubated with TSK mouse mAb or lzSI-rabbit F(ab')~ 
anti-human 3/antibody in the case of filters incubated with human 
antibodies. Filters were washed, dried, and autoradiographed  as pre- 
viously described (6). 
~esu|~ 
Specificity of Monoclonal Antitopo I Autoantibodies.  Among 
the panel of 14 TSK mouse antitopo I autoantibodies,  two 
IgG2a antibodies were chosen for this study, since it was pre- 
viously shown that  their binding  to tope I were inhibited 
by IgG from scleroderma patients positive for Sc170 antibody 
(6). The data presented in Table 1 show that TSK mouse mAbs 
GM17-1  and GM3-16,  and human mAbs  N3A,  N36,  and 
N188 obtained from scleroderma patients, exhibited significant 
binding to Sc170 and purified tope I, compared with control 
antibodies UPC10,  a BALB/c myeloma protein of the same 
isotype, or BM5 mAb (IgG1) with unknown specificity, ob- 
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Figure 1.  Schematic diagram of tope I showing the regions enclosed 
by fusion proteins A and C-H. 
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Figure 3.  Dose-effect  inhibition of binding ofTSK mAbs GM3-16 (A) 
and GM17-1 (B) by human mAbs N3A, N36, N188, and BM5. 50,000 
cpm of 12SI-labeled  TSK mAbs corresponding to 0.1 ~g were incubated 
together with various amounts of cold human mAbs. 
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Designation  of mAb  Origin  Isotype 
Binding  to: 
BSA  Scl 70  Topo I 
GM17-1  TSK mouse  IgG2a 
GM3-16  TSK mouse  IgG2a 
UPC10*  BALB/c  mouse  IgG2a 
N3A  Scleroderma patient  IgG1 
N36  Scleroderma patient  IgG1 
N188  Scleroderma patient  IgG1 
BM5S  Multiple  myeloma patient  IgG1 
325  _+  11"  5,809  _+  20  1,420  _+  65 
556  _+  48  5,359  _+  325  3,998  _+  60 
301  _+  0  509  _+  3  348  +  37 
177  _+  34  2,123  _+  25  1,766  _+  45 
54  _+  16  2,758  _+  50  1,951  _+  20 
112  _+  4  5,881  _+  157  3,062  +_  17 
68  +  6  179  +  16  120_+  3 
* cpm average _+ SD. 
* Myeloma protein  displaying/~2-6 fructosan binding  activity. 
S Human mAb with unknown binding  activity. 
tained from a patient with multiple myeloma. Higher binding 
to  commercial  Sc170  antigen  preparation  compared  with 
purified topoi enzyme might be related to the concentration 
of the enzyme in Sc170 preparation,  which is unknown,  or 
it might  be due  to the presence of other  polypeptides  that 
share cross-reactive epitopes with  topo I. Mouse antitopo  I 
antibodies tested in immunofluorescence exhibited fine speckles 
with occasional nuclear staining and perichromatin  staining 
in  metaphase  (6). 
We have previously shown that the binding of TSK mouse 
antibodies  to topo I  was not  inhibited  by type II collagen, 
dsDNA,  or RNA  polymerase (6).  Data depicted  in  Fig.  2 
show that the binding of human mAb N188  to topo I  was 
inhibited  by more than  50%  with 3  and  10/zg/ml  of topo 
I, but not with type I collagen, dsDNA, or RNA polymerase. 
These data clearly demonstrate that both human and mouse 
antibodies  are  specific for topo  I  and  Sc170. 
In further  studies,  we investigated  the  ability  of human 
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Figure 4.  Western  blot analysis. 
(/4) N188 human mAb; (8) sclero- 
derma  patient's  serum; (C)  TSK 
mAb GM3-16; (D) human myeloma 
IgG BM5. Lane I, purified topo I; 
lane 2, fusion protein A; lane 3, fu- 
sion protein C; lane 4, fusion pro- 
tein D; lane 5, fusion  protein E; lane 
6, fusion protein F; lane 7, fusion 
protein G; lane 8, fusion protein H; 
and lane 9, fusion partner protein 
GST. Each lane was loaded with 2 
#g of protein estimated by the in- 
tensity of  bands by Coomassie blue 
staining. Protein-transferred filters 
were incubated with  2 #g/ml of 
N188, GM3-16, and BM5 and 1:800 
dilution  of  scleroderma patient's 
serum for 90 min at room tempera- 
ture. The bound antibodies were re- 
vealed with rabbit F(ab')2  anti-hu- 
man 3' antibody, or rat monoclonal 
anti-mouse ~ antibody labeled  with 
12si. Table  2.  Epitope  Mapping of Human and Mouse Antitopoisomerase I Autoantibodies 
A 
Ab  Topo I  GST  270-765 
Fusion proteins of topo I polypeptide 
C  F  G  H 
1-139  453-560  555-663  658-765 
Scleroderma serum  +  -  + 
Human mAb  +  -  - 
TSK mouse mAb  +  -  - 
+  +  4-  + 
+  4-  4-  - 
+  4-  +  - 
mAbs  to  inhibit  the  binding  of t2SI-labeled TSK  mouse 
mAbs to topo I. The binding of mouse mAb GM3-16 was 
inhibited in a dose-related manner by all three human an- 
titopo I mAbs with 50%  inhibition at a concentration of 
10 #g/ml (Fig.  3 A).  In contrast, the binding of GM17-1 
was poorly inhibited by human mAbs, with only 20% inhi- 
bition at a concentration of 10/zg/ml (Fig. 3 B). These results 
demonstrate that GM3-16  and the human mAbs probably 
recognize similar or closely related epitopes. 
Western Blot Analysis.  To define the epitopes recognized 
by the TSK mouse and human mAbs, seven GST-topo I fu- 
sion proteins (see Fig. 1) were used as antigens in immuno- 
blotting experiments. The data depicted in Fig. 4 and sum- 
marized in Table 2 show that human mAb N188  binds to 
purified topo I (lane I), binds strongly to fusion protein C 
(lane 3), and very weakly to fusion proteins F and G (lanes 
6 and 7) in Fig.  4 A. Scleroderma patient's serum binds to 
purified topo I, and to fusion proteins A, C, F, G, and H 
(Fig.  4 B). Human myeloma IgG1 (BM5) did not bind to 
any of the fusion proteins (Fig.  4 D). TSK mAb GM3-16, 
like human mAb N188, binds to topo I, as well as to fusion 
proteins C, and weakly to F and G (Fig. 4 C). These results 
show that human and TSK mAbs that bind to purified topo 
I recognize a major epitope located on fusion protein C, and 
also interact weakly with epitopes present on fusion proteins 
F and G. By contrast, human polyclonal antibodies recog- 
nize additional epitopes found on fusion proteins A and H. 
Shared Id between TSK Mouse and Human mAbs.  In  a 
previous study we have described the isolation of a TSK mouse 
mAb that recognizes a cross-reactive  idiotype on TSK an- 
titopo I antibodies (6).  L350-7 is a prototype TSK mouse 
anti-topo I mAb expressing cross-reactive Id. A study of the 
expression  of this Id in 20 sera positive for Sc170 antibody, 
and 16 sera negative for Sc170 antibody from scleroderma pa- 
tients,  and 11  sera from healthy subjects  was undertaken. 
Results of this experiment showed that the reaction between 
Id and anti-Id antibody was inhibited by Ig from 16 of 20 
Sc170 positive sera,  but  not by others  (data not  shown). 
Based on this information, in further experiments, we have 
studied the ability of human mAb N188  and TSK mouse 
mAb GM3-16 to inhibit the binding of G17-13 monoclonal 
anti-Id antibody to L350-7 mAb bearing cross-reactive  Id. 
We have previously shown that L350-7 mAb bears  cross- 
reactive Id ofTSK antitopo I antibodies (6). The data depicted 
in Fig. 5 show both N188 and GM3-16 inhibited, to a similar 
extent, the binding of anti-Id antibody to L350-7 idiotype. 
These data indicate that human and mouse antibodies with 
the same fine specificity share an interspecies cross-reactive Id. 
Discussion 
Autoimmune diseases are commonly associated with anti- 
bodies  against  cytoplasmic or  nuclear enzymes (e.g.,  an- 
tithyroid peroxidase  autoantibodies in Hashimoto thyroid- 
itis [10], antipyruvate dehydrogenase complex antibodies in 
primary biliary cirrhosis [11], antiglutamic acid decarboxy- 
lase antibodies in insulin-dependent diabetes [12], anti-H K 
ATPase antibodies in pernicious anemia [13], and antibodies 
to t-RNA synthetases in polymyositis [14]. There is a lack 
of information on the epitope specificities of autoantibodies 
against these enzyme autoantigens. Antibodies against topo 
I are found in scleroderma, but not in other systemic autoim- 
mune diseases. D'Apra et al. (15) have shown that sderoderma 
sera contain antitopo I antibodies that bind to at least two sets 
of epitopes  present  in fusion proteins,  one in amino acid 
residues 171-484,  and the other in the 281 COOH-terminal 
residues.  Piccini et al. (16), using a different panel of fusion 
proteins, found that a set of epitopes present between amino 
acid residues 405-485  are recognized by sderoderma sera. Our 
results presented here also show that polyclonal autoantibodies 
present in scleroderma sera react with several epitopes.  It is 
not clear from these observations whether the antibodies that 
react with a dominant epitope also cross-react  with other 
epitopes,  or whether specific antibodies recognize each epi- 
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Figure 5.  Competitive  inhibition 
of the binding of lzsI-labeled G17- 
13 monoclonal  anti-ld antibody to 
L350-7 antitopo I mAb by TSK mAb 
GM3-16 and human  mAb N188 anti- 
topo I antibody.  L350-7 is a prototype 
of TSK antitopo I mAb expressing 
cross-reactive  Id (see reference  6). The 
expression of cross-reactive Id was 
studied by  competitive inhibition 
RIA, in which microtiter plates were coated with 10/zg L350-7 mAb, 
and then incubated  with 50,000 cpm of tzSI-GM17-13 anti-Id  mAb, and 
various amounts  of  inhibitor  antibodies,  simultaneously.  UPC10  is a BALB/c 
IgG2a with 32-6 fructosan  binding activity,  and BM5 is a human lgG1 
myeloma protein. 
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Figure 6.  Comparison of amino acid se- 
quences  of  regions showing  greatest  similarity 
between fusion protein C and fusion proteins 
F, G, or UL70 of  CMV. (:) Amino  acid  identi- 
ties between  fusion protein C and fusion pro- 
teins F, G, or UL70 of  CMV, and (.) conserved 
changes. Underlined  portions are hydrophilic 
regions of fusion protein C. 
tope because of the polyclonal nature of antibodies used in 
these studies. 
In our study, we used mAbs obtained from humans with 
scleroderma and TSK mice, and fusion proteins corresponding 
to various fragments of topo I to define the epitopes recog- 
nized by autoantibodies. Our results show for the first time 
that human and mouse TSK mAbs, react primarily with a 
single  fusion  protein  (C)  containing  the  NH2-terminal 
amino acid residues 1-139.  These were also found to react 
weakly with fusion proteins F and G bearing residues 453-663. 
The weaker binding of these autoantibodies to fragments F 
and G could be due to partial sequence homology between 
the reactive epitopes present in these fragments and the dom- 
inant epitope present in peptide C.  To investigate this, we 
compared sequences of C, F, and G fusion proteins and found 
several shared amino acid residues.  The data depicted in Fig. 
6 show that the amino acid sequence 9-20 and 117-130  of 
C shares three and four residues with both F and G, and the 
sequences 44-52,  90-100,  and 129-137  share three residues 
with E  The hydrophobicity analysis of the amino acid se- 
quence of topo I (data not shown), particularly C fusion pro- 
tein,  shows seven hydrophilic regions (1-7,  11-18,  46-50, 
92-98, 106-113,  121-126, and 131-135) that could be poten- 
tially involved in the binding of antibodies.  Two of these, 
found in the region 9-20 and 117-130,  share residues with 
F and G fusion proteins. Shared amino acid residues, and par- 
ticularly where sequential, such as those found in 9-20 and 
117-130 regions, could be responsible for the cross-reactivity 
of mAbs with C,  F,  and G  fusion proteins. 
The mechanisms leading to the breakdown of tolerance 
against enzyme autoantigen molecules located in the cytoplasm 
or nucleus is poorly understood. There are several possibili- 
ties to activate T  or B lymphocytic clones specific for en- 
zyme autoantigens such as topo I.  One is that subsequent 
to the translocation of nuclear enzymes to the cell surface, 
either under physiological conditions or subsequent to pri- 
mary injury, the enzyme can be taken up by APCs, processed, 
and seen by T  cells. Bachmann et al.  (17) recently showed 
the La antigen, a ribonucleoprotein, is translocated to the 
surface of CV-1 cells, and that a minor fraction is associated 
with extracellular fibronectin network. Another is activation 
of autoreactive clones by antigens (i.e., enzymes) from different 
species. Foreign enzymes can activate T cells that could then 
provide help for autoreactive B cells. It was recently shown 
that anti-DNA antibodies can be produced in animals im- 
munized with bacterial DNA (18). Still another is by molec- 
ular mimicry, namely by unrelated antigens. Rheumatic fever 
is a classic example of a disease caused by molecular mimicry. 
Antibodies against group A streptococci M protein are cross- 
reactive with cardiac myosin (19, 20).  They also cross-react 
with the cytoplasm of neurons in rheumatic chorea (21). There 
are increasing examples of the presence of shared sequences 
between viral, bacterial,  parasitic, and auto-antigens (22) that 
can be responsible for molecular mimicry￿9 
Maul et al.  (23) have reported that topo I and retroviral 
protein p30gag have some sequence similarity. The sequence 
of topo I contains six sequential residues shared with p30gag 
group specific protein of type C mammalian retroviruses. We 
compared the sequence of C  fusion protein with those in 
the DNASIS database,  and found that it shares five sequen- 
tial residues 121-126 with UL70 protein of human cytomeg- 
alovirus.  Studies are in progress to determine whether an- 
titopo I autoantibodies from patients with scleroderma bind 
to  the  CMV  protein  containing  these  five  homologous 
residues,  or if the CMV peptide inhibits the binding of au- 
toantibodies to topo I. 
It is interesting to note that  sequences of housekeeping 
enzymes in general, and enzymes involved in nucleic acid me- 
tabolism in particular, are quite conserved. Some of the au- 
toantibodies against these enzymes even inhibit the catalytic 
activity￿9 Thus, some antitopo I autoantibodies inhibit con- 
version of supercoiled DNA into a relaxed form (23),  and 
anti-RNA polymerase antibodies inhibit the enzymatic ac- 
tivity (24).  Because of the high degree of conservation of 
sequence homology between enzymes from different species, 
human and TSK mouse antitopo I autoantibodies bind to 
very similar or identical epitopes. Analysis of V gene reper- 
toire and sequence determination of the mAbs will shed more 
light on the origin and generation of diversity of autoanti- 
bodies with similar fine specificities  in different species￿9 
Furthermore, our studies reveal that human and murine 
mAbs with the same immunochemical fine specificity,  also 
share an interspecies cross-reactive Id. Similar observations 
have been made for anti-Sm antibodies in the MRL mouse 
and human SLE. Takei et al. (25),  demonstrated that rabbit 
antiserum raised against a peptide corresponding to the CDR2 
region of human anti-Sm antibody reacted with the corre- 
sponding peptide of mouse CDR2 region. They also showed 
that these anti-Id antibodies recognized mouse and human 
Ig H  chains in Western blot analysis.  Our studies suggest 
that V genes encoding autoantibodies specific for nuclear an- 
tigens are conserved during evolution, as is to be the case 
with anti-Sin (25)  and anti-DNA antibodies (26). 
Our results are important for three reasons￿9 The first is 
the demonstration that B cell clones producing antitopo I 
antibodies with the same specificity are present in the human 
1107  Muryoi  et al. and mouse repertoire, and are activated during the course of 
disease, in scleroderma patients and TSK mice. Second, the 
presence of interspecies cross-reactive Id among antitopo I 
autoantibodies suggests a conservation of DNA segments en- 
coding autoantibodies during evolution. Third,  the use of 
fusion proteins could allow correlation between the presence 
of antibodies to specific epitopes, and the clinical features of 
autoimmune disease. Such studies may also provide insight 
into the pathogenesis of human scleroderma and TSK mouse 
disease. 
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